Company: Gloucester Pharmaceuticals
Based: Cambridge, MA
Investors: Prospect Venture Partners, Individuals, ProQuest Investments, CIBC Capital Partners, Undisclosed Firm
Scoop: Gloucester Pharmaceuticals acquires clinical-stage oncology drug candidates and advances them through regulatory approval and commercialization. It's most advanced drug program is romidepsin, a histone deacetylase (HDAC) inhibitor in Phase III trials for T-cell lymphomas.